LAB vs VICI · rev $174.4M vs P/E 9.3, rev $3.85B
Standard Biotools Inc (LAB) versus VICI Properties Inc (VICI) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
VICI Properties Inc (VICI) is a reit - diversified company listed on NYSE.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported VICI revenue for 2024-12-31 was $3.85B. Net income was $2.72B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
LAB currently screens at market cap $317.1M. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
Not investment advice. Open the LAB and VICI stock pages for the full models.
Not investment advice.